NASDAQ: QUREUniqure Nv Stock
$4.75-0.07 (-1.45%)
Updated Apr 23, 2024
QURE Price
$4.75
Fair Value Price
$15.53
Market Cap
$227.23M
52 Week Low
$4.61
52 Week High
$22.48
P/E
-0.73x
P/B
1.09x
P/S
20.37x
PEG
N/A
Dividend Yield
N/A
Revenue
$15.84M
Earnings
-$308.48M
Gross Margin
14%
Operating Margin
-1,672.66%
Profit Margin
-1,947.1%
Debt to Equity
3.01
Operating Cash Flow
-$146M
Beta
1.09
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
QURE Overview
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how QURE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QURE ($4.75) is undervalued by 69.41% relative to our estimate of its Fair Value price of $15.53 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
QURE ($4.75) is significantly undervalued by 69.41% relative to our estimate of its Fair Value price of $15.53 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
QURE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more QURE due diligence checks available for Premium users.
Be the first to know about important QURE news, forecast changes, insider trades & much more!
QURE News
Valuation
QURE fair value
Fair Value of QURE stock based on Discounted Cash Flow (DCF)
Price
$4.75
Fair Value
$15.53
Undervalued by
69.41%
QURE ($4.75) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
QURE ($4.75) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
QURE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
QURE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.73x
Industry
16.46x
Market
41.92x
QURE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.09x
Industry
5.93x
QURE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
QURE's financial health
Profit margin
Revenue
$6.7M
Net Income
-$73.2M
Profit Margin
-1,094.4%
QURE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
QURE's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$831.7M
Liabilities
$624.0M
Debt to equity
3.01
QURE's short-term assets ($651.85M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QURE's short-term assets ($651.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QURE's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
QURE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$49.5M
Investing
$59.6M
Financing
$46.0k
QURE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
QURE vs Biotech Stocks
Uniqure Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.